Pulse lineResearch With Heart Logo

Longer-term Lipid-lowering Drug Use and Risk of Incident and Fatal Prostate Cancer in Black and White Men in the ARIC Study.

TitleLonger-term Lipid-lowering Drug Use and Risk of Incident and Fatal Prostate Cancer in Black and White Men in the ARIC Study.
Publication TypeJournal Article
Year of Publication2018
AuthorsMondul AM, Joshu CE, Barber JR, Prizment AE, Bhavsar NA, Selvin E, Folsom AR
Secondary AuthorsPlatz EA
JournalCancer Prev Res (Phila)
Volume11
Issue12
Pagination779-788
Date Published2018 12
ISSN1940-6215
KeywordsAfrican Americans, Atherosclerosis, European Continental Ancestry Group, Follow-Up Studies, Health Status Disparities, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Incidence, Male, Middle Aged, Prospective Studies, Prostatic Neoplasms, Risk Assessment, Risk Factors, Survival Rate, Time Factors, United States
Abstract

Lipid-lowering medications, particularly statins, may protect against aggressive prostate cancer. Fatal prostate cancer, the most clinically relevant outcome, remains understudied for this association. We prospectively studied lipid-lowering medication use and both incident and fatal prostate cancer in black and white men in the Atherosclerosis Risk in Communities (ARIC) study. A total of 6,518 men without cancer at visit 2 (1990-1992), the start of the statin era, were followed for prostate cancer incidence and death through 2012. Medication use was collected during study visits and telephone calls at up to nine time points during follow-up. Cox regression was used to estimate HR and 95% confidence intervals (CI) of total (white = 541, black = 259) and fatal (white = 56, black = 34) prostate cancer overall and by race. Lipid-lowering medication use was modeled as time-dependent current use or duration (never,

DOI10.1158/1940-6207.CAPR-17-0396
Alternate JournalCancer Prev Res (Phila)
PubMed ID30327368
PubMed Central IDPMC6289799
Grant ListP30 CA006973 / CA / NCI NIH HHS / United States
R01 DK089174 / DK / NIDDK NIH HHS / United States
HHSN268201700001I / HL / NHLBI NIH HHS / United States
K24 DK106414 / DK / NIDDK NIH HHS / United States
HHSN268201700004I / HL / NHLBI NIH HHS / United States
HHSN268201700002I / HL / NHLBI NIH HHS / United States
HHSN268201700005I / HL / NHLBI NIH HHS / United States
U01 CA164975 / CA / NCI NIH HHS / United States
HHSN268201700003I / HL / NHLBI NIH HHS / United States
K01 HL140146 / HL / NHLBI NIH HHS / United States